These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30553548)

  • 1. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
    Ono A; Isaka M; Serizawa M; Omae K; Kojima H; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Urakami K; Nagashima T; Sugino T; Kusuhara M; Takahashi T; Yamaguchi K; Ohde Y
    Lung Cancer; 2019 Feb; 128():152-157. PubMed ID: 30553548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 3. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
    Devarakonda S; Rotolo F; Tsao MS; Lanc I; Brambilla E; Masood A; Olaussen KA; Fulton R; Sakashita S; McLeer-Florin A; Ding K; Le Teuff G; Shepherd FA; Pignon JP; Graziano SL; Kratzke R; Soria JC; Seymour L; Govindan R; Michiels S
    J Clin Oncol; 2018 Oct; 36(30):2995-3006. PubMed ID: 30106638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
    Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
    Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
    Zhang J; Chen N; Qi J; Zhou B; Qiu X
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
    Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
    Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
    Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
    Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
    Wan YW; Beer DG; Guo NL
    Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.
    Ludovini V; Bellezza G; Pistola L; Bianconi F; Di Carlo L; Sidoni A; Semeraro A; Del Sordo R; Tofanetti FR; Mameli MG; Daddi G; Cavaliere A; Tonato M; Crinò L
    Ann Oncol; 2009 May; 20(5):842-9. PubMed ID: 19153117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
    Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
    Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
    J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
    Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
    Interact Cardiovasc Thorac Surg; 2013 Feb; 16(2):166-72. PubMed ID: 23143203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.
    Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2139-2146. PubMed ID: 30034229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
    Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
    J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of nuclear factor of activated T-cells 5 expression in non-small cell lung cancer patients who underwent surgical resection.
    Cho HJ; Yun HJ; Yang HC; Kim SJ; Kang SK; Che C; Lee SD; Kang MW
    J Surg Res; 2018 Jun; 226():40-47. PubMed ID: 29661287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.